Clinical Trial Update: A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China [Phase 3]

View source ↗

Summary

A Phase 3 sub-study comparing epcoritamab to investigator's choice chemotherapy in relapsed/refractory diffuse large B-cell lymphoma in China; the trial status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)

Snippet

Sponsor: Genmab | Conditions: Diffuse Large B-Cell Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING